Nicky Liebermann

520 total citations
28 papers, 359 citations indexed

About

Nicky Liebermann is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nicky Liebermann has authored 28 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nicky Liebermann's work include Breast Cancer Treatment Studies (9 papers), Advanced Breast Cancer Therapies (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Nicky Liebermann is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), Advanced Breast Cancer Therapies (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Nicky Liebermann collaborates with scholars based in Israel, United States and Austria. Nicky Liebermann's co-authors include Ariel Hammerman, Shmuel Klang, Noa Efrat, John Hornberger, Julie Doberne, Lior Soussan‐Gutman, Shulamith Rizel, Liat Lerner‐Geva, Noa Ben-Baruch and Salomon M. Stemmer and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Cancer Research.

In The Last Decade

Nicky Liebermann

24 papers receiving 353 citations

Peers

Nicky Liebermann
L. Winterbottom United Kingdom
A Hacking Switzerland
Chan Seok Yoon South Korea
Hyma Schubert Switzerland
André Mattar Brazil
Maria Rica Mirasol‐Lumague Philippines
Farid Jamshidian United States
Nicola Roche United Kingdom
Silvia Pecchio Italy
Karen Daily United States
L. Winterbottom United Kingdom
Nicky Liebermann
Citations per year, relative to Nicky Liebermann Nicky Liebermann (= 1×) peers L. Winterbottom

Countries citing papers authored by Nicky Liebermann

Since Specialization
Citations

This map shows the geographic impact of Nicky Liebermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicky Liebermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicky Liebermann more than expected).

Fields of papers citing papers by Nicky Liebermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicky Liebermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicky Liebermann. The network helps show where Nicky Liebermann may publish in the future.

Co-authorship network of co-authors of Nicky Liebermann

This figure shows the co-authorship network connecting the top 25 collaborators of Nicky Liebermann. A scholar is included among the top collaborators of Nicky Liebermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicky Liebermann. Nicky Liebermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Säemann, Marcus D., et al.. (2025). Cardio-renal-metabolic (CRM): Call for action for European Guidelines for Primary Care Physicians. Journal of Primary Care & Community Health. 16. 3032596–3032596.
2.
Hubert, Ayala, Sofia Man, Ravit Geva, et al.. (2024). Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data. ESMO Open. 9(8). 103648–103648. 1 indexed citations
3.
4.
Brenner, Baruch, Ayala Hubert, Sofia Man, et al.. (2023). Treatments and clinical outcomes in stage II colon cancer (CC) patients (pts) with 12-gene Oncotype DX Colon Recurrence Score assay-guided therapy: Real-world data.. Journal of Clinical Oncology. 41(16_suppl). 3620–3620.
5.
Siegelmann‐Danieli, Nava, et al.. (2023). Is access to adjuvant treatments prioritized over therapies for metastatic cancer? The Israeli experience.. Journal of Clinical Oncology. 41(16_suppl). e18599–e18599. 2 indexed citations
6.
Stemmer, Salomon M., Mariana Steiner, Shulamith Rizel, et al.. (2019). Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy. npj Breast Cancer. 5(1). 41–41. 23 indexed citations
7.
Ben‐Aharon, Irit, Tal Goshen‐Lago, Sara Morgenstern, et al.. (2019). Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location. The Oncologist. 24(8). e696–e701. 8 indexed citations
8.
Stemmer, Salomon M., Shulamith Rizel, David Geffen, et al.. (2017). Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. npj Breast Cancer. 3(1). 32–32. 68 indexed citations
9.
Ben‐Aharon, Irit, Tal Goshen‐Lago, Ravit Geva, et al.. (2017). Sidedness matters: Surrogate biomarkers prognosticate colorectal cancer upon anatomic location.. Journal of Clinical Oncology. 35(4_suppl). 523–523. 1 indexed citations
10.
11.
Sulkes, Aarón, Tzippy Shochat, Daliah Tsoref, et al.. (2016). Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Research and Treatment. 157(3). 511–516. 29 indexed citations
12.
13.
Brenner, Baruch, Ravit Geva, Megan Rothney, et al.. (2015). Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. Value in Health. 19(1). 82–87. 13 indexed citations
14.
15.
Liebermann, Nicky, et al.. (2011). [Identification of K-RAS mutations in colorectal cancer patients in Israel].. PubMed. 150(5). 447–50, 491. 6 indexed citations
16.
Meyer, Joachim, Yisrael Parmet, Yaakov Henkin, et al.. (2011). Adherence by primary care physicians to guidelines for the clinical management of dyslipidemia.. PubMed. 13(11). 657–62. 6 indexed citations
17.
Baehner, Frederick L., et al.. (2011). Evaluation of recurrence score and traditional clinicopathologic metrics in a large ER-positive, lymph node–negative patient cohort.. Journal of Clinical Oncology. 29(27_suppl). 30–30. 2 indexed citations
18.
Klang, Shmuel, Ariel Hammerman, Nicky Liebermann, et al.. (2010). Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization. Value in Health. 13(4). 381–387. 94 indexed citations
19.
Liebermann, Nicky, et al.. (2010). The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.. Journal of Clinical Oncology. 28(15_suppl). 6075–6075. 3 indexed citations
20.
Goldfracht, Margalit, Avi Porath, & Nicky Liebermann. (2005). ‘Diabetes in the community’: a nationwidediabetes improvement programme inprimary care in Israel. Quality in primary care. 13(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Winterbottom Breakdown of academic impact, for papers by A Hacking Breakdown of academic impact, for papers by Chan Seok Yoon Breakdown of academic impact, for papers by Hyma Schubert Breakdown of academic impact, for papers by André Mattar Breakdown of academic impact, for papers by Maria Rica Mirasol‐Lumague Breakdown of academic impact, for papers by Farid Jamshidian Breakdown of academic impact, for papers by Nicola Roche Breakdown of academic impact, for papers by Silvia Pecchio Breakdown of academic impact, for papers by Karen Daily
Rankless by CCL
2026